RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 113 filers reported holding RIGEL PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 3.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,566,573 | -17.4% | 14,413,495 | -1.4% | 0.00% | -100.0% |
| Q2 2023 | $18,856,694 | +1.2% | 14,617,592 | +3.5% | 0.00% | 0.0% |
| Q1 2023 | $18,641,254 | -15.4% | 14,122,161 | -3.8% | 0.00% | 0.0% |
| Q4 2022 | $22,021,598 | +15.3% | 14,681,064 | -9.3% | 0.00% | 0.0% |
| Q3 2022 | $19,093,000 | +2.8% | 16,180,237 | -1.5% | 0.00% | 0.0% |
| Q2 2022 | $18,564,000 | -62.5% | 16,427,721 | -0.9% | 0.00% | 0.0% |
| Q1 2022 | $49,555,000 | +13.0% | 16,573,646 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $43,864,000 | -27.8% | 16,551,984 | -1.1% | 0.00% | -50.0% |
| Q3 2021 | $60,739,000 | -16.5% | 16,732,300 | -0.1% | 0.00% | 0.0% |
| Q2 2021 | $72,707,000 | +20.8% | 16,752,909 | -4.8% | 0.00% | 0.0% |
| Q1 2021 | $60,203,000 | -1.7% | 17,603,163 | +0.6% | 0.00% | 0.0% |
| Q4 2020 | $61,227,000 | +48.4% | 17,493,420 | +1.7% | 0.00% | 0.0% |
| Q3 2020 | $41,267,000 | +31.0% | 17,194,436 | -0.1% | 0.00% | +100.0% |
| Q2 2020 | $31,510,000 | +35.7% | 17,219,104 | +15.7% | 0.00% | 0.0% |
| Q1 2020 | $23,214,000 | -26.3% | 14,881,803 | +1.2% | 0.00% | 0.0% |
| Q4 2019 | $31,477,000 | +13.4% | 14,708,285 | -0.9% | 0.00% | 0.0% |
| Q3 2019 | $27,762,000 | -23.5% | 14,845,751 | +6.8% | 0.00% | -50.0% |
| Q2 2019 | $36,297,000 | +0.7% | 13,907,023 | -0.8% | 0.00% | 0.0% |
| Q1 2019 | $36,029,000 | +14.1% | 14,018,349 | +2.1% | 0.00% | 0.0% |
| Q4 2018 | $31,567,000 | -27.9% | 13,724,460 | +0.7% | 0.00% | 0.0% |
| Q3 2018 | $43,767,000 | +15.5% | 13,635,104 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $37,901,000 | -3.4% | 13,392,367 | +20.9% | 0.00% | 0.0% |
| Q1 2018 | $39,222,000 | -10.0% | 11,079,869 | -1.3% | 0.00% | 0.0% |
| Q4 2017 | $43,556,000 | +84.4% | 11,225,669 | +20.7% | 0.00% | +100.0% |
| Q3 2017 | $23,623,000 | -10.6% | 9,300,671 | -3.9% | 0.00% | 0.0% |
| Q2 2017 | $26,411,000 | -21.5% | 9,674,514 | -4.8% | 0.00% | -50.0% |
| Q1 2017 | $33,644,000 | +65868.6% | 10,164,146 | +47030.4% | 0.00% | – |
| Q4 2016 | $51,000 | -79.4% | 21,566 | -67.9% | 0.00% | – |
| Q3 2016 | $247,000 | +274.2% | 67,161 | +127.1% | 0.00% | – |
| Q2 2016 | $66,000 | +500.0% | 29,568 | +433.0% | 0.00% | – |
| Q1 2016 | $11,000 | +83.3% | 5,547 | +162.0% | 0.00% | – |
| Q4 2015 | $6,000 | +20.0% | 2,117 | 0.0% | 0.00% | – |
| Q3 2015 | $5,000 | -28.6% | 2,117 | 0.0% | 0.00% | – |
| Q2 2015 | $7,000 | -12.5% | 2,117 | 0.0% | 0.00% | – |
| Q1 2015 | $8,000 | +60.0% | 2,117 | 0.0% | 0.00% | – |
| Q4 2014 | $5,000 | 0.0% | 2,117 | -25.3% | 0.00% | – |
| Q3 2014 | $5,000 | -54.5% | 2,835 | 0.0% | 0.00% | – |
| Q2 2014 | $11,000 | -15.4% | 2,835 | -14.2% | 0.00% | – |
| Q1 2014 | $13,000 | +44.4% | 3,304 | 0.0% | 0.00% | – |
| Q4 2013 | $9,000 | -25.0% | 3,304 | 0.0% | 0.00% | – |
| Q3 2013 | $12,000 | +9.1% | 3,304 | 0.0% | 0.00% | – |
| Q2 2013 | $11,000 | – | 3,304 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |